[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of California, Berkeley\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":399},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,51,80,118,146,170,197,221,244,263,286,322,349,375],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100638090","phase-4-ocular-surface-health-and-tear-film-stability-with-a-nasal-spray-dry-eye-treatment-100638090",false,"NCT07606625","Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment","The Impact of Varenicline Nasal Spray 0.03mg Dry Eye Treatment on Ocular Surface Health, Tear Film Stability, and Ocular Discomfort","Inclusion Criteria:\n\n* Is 18 years of age and has full legal capacity to volunteer (no max age requirement)\n* Baseline Ocular Surface Disease Index (OSDI) \\>13\n* Has mild to moderate MGD\n* Has best corrected visual acuity of 20\u002F40 or better\n* Has had an oculo-visual examination in the last two years\n* Is willing to continue other daily dry eye management regimen (e.g., warm compresses, and\u002For eyelid margin cleaning)\n* Is willing to discontinue other prescription medications for dry eye disease (DED) management\n* Is willing to stop any topical eye drops before all planned visits\n* Has read, understood, and completed the informed consent letter\n\nExclusion Criteria:\n\n* Is participating in any other type of clinical or research study\n* Is currently pregnant, nursing, lactating, or planning a pregnancy\n* Is currently having \\>50% blockage of Meibomian glands in more than two eyelids or significant atrophy (i.e., severe MGD)\n* Is currently using any topical ocular medications\n* Has chronic or currently active sinus related problems\n* Has blepharitis \\> grade 1\n* Has active ocular infections\n* Has a condition or in a situation which, in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation in the study\n* Has received Rx DED treatment within one week of enrollment\n* Has received any thermal or light-based DED treatment within 30 days of enrollment\n* Has significant corneal epithelial defects\n* Has abnormal eyelid anatomy\n* Has corneal neuropathic pain\n* Has chronic or recurrent epistaxis (nosebleeds), coagulation disorders, or other conditions that may have led to a clinically significant increased risk of bleeding\n* Has any intraocular surgery including trabeculectomy (MIGS, laser, or small incision glaucoma surgery allowed), extraocular surgery in either eye within 3 months, or refractive surgery within 12 months of enrollment\n* Has a known allergy to a product used in this study","ALL","18 Years",{"count":19,"type":20},65,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).",[26,27],"Dry Eye","Meibomian Gland Dysfunction",[29,30,31,32,33,34,35,36,37],"Dry eye disease","Meibomian gland dysfunction","Varenicline","Nasal spray dry eye treatment","Tear lipid layer","Tear thinning","Tear production","Tear film stability","Ocular discomfort","RECRUITING","2026-05-22",{"date":41,"type":42},"2026-05-27","ACTUAL",{"date":44,"type":42},"2026-03-06",{"date":46,"type":20},"2026-12-31",{"name":48,"class":49},"University of California, Berkeley","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100637193","evaluating-in-line-chlorination-in-nigeria-100637193","NCT07601503","Evaluating In-line Chlorination in Nigeria","In-line Chlorination for Drinking Water Treatment in Nigeria","Inclusion Criteria:\n\n* Adult (18+) or emancipated minor (15+) pregnant women and women with children under 5 years old who do not plan to permanently move in the next 12 months.\n* Must be knowledgeable about the household's water collection and management practices\n\nExclusion Criteria:\n\n* Non-age-eligible women. Men and non-emancipated minors. Women who do not consent.",true,"15 Years",{"count":61,"type":20},2655,[63],"NA","This study evaluates the implementation and effectiveness of in-line chlorination (ILC) for improving drinking water quality in rural Nigeria. Unsafe drinking water remains a major contributor to diarrheal disease, particularly among children under five. Inline chlorination is a passive water treatment approach that automatically doses chlorine at community water systems without requiring electricity or daily user action. Two cluster randomized controlled trials will be conducted in Kano State (North-West Nigeria) and Cross River State (South-South Nigeria). Communities will be randomized to either receive in-line chlorination installed at eligible communal water systems or serve as controls with no chlorination. The unit of randomization is a community or a cluster of communities that share water system for drinking water. The primary objective is to estimate the causal impact of in-line chlorination on household drinking water quality. Outcomes include the prevalence of Escherichia coli contamination in tap water and stored household water as well as the presence of free chlorine residual. Secondary objectives assess water source usage and adoption of chlorinated sources, as well as reduction in diarrheal disease. Implementation fidelity and operational performance of chlorination devices will also be monitored.",[66,67,68],"Diarrhea","Water Quality","Adoption",[70],"Inline Chlorination, Safe Water, Water Practices, Behavior, Diarrhea, Children","NOT_YET_RECRUITING","2026-05-14",{"date":39,"type":42},{"date":75,"type":20},"2026-05-26",{"date":77,"type":20},"2027-12-31",{"name":48,"class":49},2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":100,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},"100614570","aphasia-physical-exercise-study-randomized-trial-100614570","NCT07281313","Aphasia Physical EXercise Study: Randomized Trial","High-intensity Exercise in Stroke Recovery: Randomized Trial","APEX","Inclusion Criteria:\n\n* Aphasia following ischemic or hemorrhagic stroke\n* Aphasia as determined by a standardized language test (Western Aphasia Battery Aphasia Quotient \\\u003C 93.8 at study intake)\n* At least 6 months from the last stroke\n* Proficient in English before the stroke\n* At least 8 years of education\n* Between the ages of 18 and 80\n* Independent with ambulation without a device (single-point cane accepted)\n* Medically stable with no contraindications to participate in regular physical exercise as determined by the patients' own primary care provider or other treating provider.\n\nExclusion Criteria:\n\n* Prior history of dementia, neurologic illness (other than stroke), or recent (last 3 years) substance abuse\n* Significant visual or hearing disabilities (e.g., neglect, uncorrected visual or hearing loss) that interfere with testing\n* Self-report uncontrolled cardiorespiratory and\u002For metabolic disorders incompatible with exercise","80 Years",{"count":90,"type":20},120,[63],"The goal of this clinical trial is to evaluate the effects of a high-intensity exercise program on recovery in individuals with post-stroke aphasia. The high-intensity exercise program has been specifically designed for individuals with post-stroke aphasia and includes an interval training full-body workout, which can increase cardiovascular fitness, improve muscle strength and motor performance, and maximize cognitive and language gains. The main question this study aims to answer is:\n\n• Does participation in a high-intensity exercise program lead to changes in physical health, language, cognitive, motor recovery, psychological and\u002For psychosocial domains?\n\nParticipants will be randomly assigned to either a high-intensity exercise program (target intervention) or a low-intensity exercise program (control intervention) delivered over 12-weeks in a group setting.\n\nOutcome measures will be collected once immediately after the intervention period and once during the following 12-week maintenance period to capture short- and long-term effects of the exercise program.",[94,95,96,97,98,99],"Aphasia, Acquired","Aphasia","Aphasia, Fluent","Aphasia, Non-fluent","Aphasia Following Cerebral Infarction","Aphasia Following Nontraumatic Intracerebral Hemorrhage",[101,102,103,104,105,106,107,108],"aphasia","physical exercise","high intensity interval training","cognition","physical fitness","balance","stroke","language","2026-03-17",{"date":111,"type":42},"2026-03-19",{"date":113,"type":42},"2025-12-01",{"date":115,"type":20},"2030-03-01",{"name":48,"class":49},4,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":50},"100591348","heat-stress-exposure-among-low-income-residents-in-bangladesh-and-evaluation-of-indoor-interventions-100591348","NCT06979258","Heat Stress Exposure Among Low-Income Residents in Bangladesh and Evaluation of Indoor Interventions","Heat Stress: Exposure Among Low-Income Residents in Bangladesh and Evaluation of Indoor Interventions","Inclusion Criteria for the house:\n\n* House is located in an informal settlement in an urban area in Bangladesh\n* The house has a corrugated iron roof and corrugated iron walls\n* The household plans to remain in the house from Feb-Nov\n\nExclusion Criteria for the house\n\n* There is an inhabited structure about the house\n* The landlord does not allow the proposed intervention\n\nInclusion Criteria for the participant:\n\n* Lives in an eligible household\n\nExclusion Criteria for the participant\n\n* Has access to air conditioning in their home or place of work\n* Reports they are pregnant\n* Has hypertension, as measured by study staff\n* Has diabetes, as measured by study staff\n* Self-reports cardiovascular disease \u002F chronic cardiac condition\n* Self-reports respiratory disease \u002F chronic respiratory condition",{"count":126,"type":20},1539,[63],"The goal of this clinical trial is to learn if infrastructure and equipment installed to cool homes reduce adverse health outcomes. The main questions it aims to answer are:\n\nWhat is the impact of the intervention on indoor heat stress? What is the impact of the intervention on personal exposure to heat stress? What is the impact of the intervention on health outcomes, including heart rate, and heart rate variability, and sleep quality?\n\nParticipants will have cooling infrastructure and\u002For equipment installed in their home; have heat stress sensors installed inside and outside their home and wear personal heat stress monitors; allow some biological functions such as heat rate, heat rate variability, and sleep quality.",[130],"Heat Stress",[132,133,134,135,136,137],"heat stress","cooling","heart rate","heart rate variability","sleep quality","Bangladesh","2026-02-17",{"date":140,"type":42},"2026-02-20",{"date":142,"type":42},"2025-05-12",{"date":144,"type":20},"2029-03-31",{"name":48,"class":49},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":50},"100388054","isolating-and-mitigating-sequentially-dependent-perceptual-errors-in-clinical-visual-search-100388054","NCT04332783","Isolating and Mitigating Sequentially Dependent Perceptual Errors in Clinical Visual Search","Inclusion Criteria:\n\n* Subjects must have normal or corrected to normal vision with contacts or glasses.\n\nExclusion Criteria:\n\n* Subjects may not be under the age of 18 to participate.\n* Subjects may not participate if they are blind.",{"count":153,"type":20},10120,[63],"Remote-store-and-forward teledermatology has recently grown exponentially in popularity and use as an efficient, accurate, and cost-effective way to improve the health and well-being of countless patients. Despite advances in machine learning and computer vision, the screening and reading of dermatological images still depends on the visual system of human observers (e.g., clinicians), who receive extensive training to best recognize lesions and anomalies. In remote store-and-forward teledermatology settings, clinicians may examine hundreds of images on a daily basis, seeing several images one after the other. A main underlying assumption of their work is that clinician percepts and decisions about a current image are completely independent from prior viewings. However, we and other groups demonstrated that the visual system has visual serial dependencies (VSDs) at many levels, from perception to decision making, including in clinical tasks. These sequential dependencies, replicated hundreds of times in the literature, mean that what was seen in the past influences (and captures) what is seen and reported at this moment. Theoretically, VSDs are helpful in an autocorrelated natural world, but they are suboptimal in visual tasks conducted in artificial situations where images are not always related. Importantly, serial dependencies in perceptual processing could thus produce significant errors during diagnostic judgments of dermatological images. Our central hypothesis is that VSD can have a disruptive effect in asynchronous remote-store-and-forward teledermatology judgments that impairs accurate detection and recognition of lesions. This hypothesis is supported by our robust pilot data, which show that VSD strongly biases lesion classification in both untrained observers and expert clinicians. The rationale for the proposed research projects is that once it is known how serial dependence arises and how it impacts judgments, we can understand how to control for it. Hence, accuracy of lesion detection and diagnosis can significantly improve. The specific objectives of this proposal are to establish (Aim 1), identify (Aim 2) and mitigate (Aim 3) the impact of VSD on remote-store-and-forward dermatological judgments.",[157],"Vision",[159,160,161],"Visual Perception","Psychophysics","Visual Search","2026-01-30",{"date":164,"type":42},"2026-02-03",{"date":166,"type":42},"2019-04-01",{"date":168,"type":20},"2032-10-30",{"name":48,"class":49},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":50},"100558767","healthy-lifestyles-in-bipolar-disorder-bay-area-study-100558767","NCT06555406","Healthy Lifestyles in Bipolar Disorder: Bay Area Study","Time-restricted Eating as an Adjunctive Intervention for Bipolar Disorder","Inclusion Criteria:\n\n* Meets diagnostic criteria for bipolar I disorder or bipolar II disorder (but not cyclothymia, bipolar disorder Not otherwise specified or bipolar disorder due to another medical condition) assessed by the Diagnostic Interview for Anxiety, Mood, and Obsessive-compulsive and Related Neuropsychiatric Disorders \\[DIAMOND\\])\n* current sleep (insomnia, hypersomnolence) or circadian sleep-wake (delayed phase, advanced phase, irregular sleep-wake, non-24-hour sleep-wake-type) concerns indicated by endorsement of at least some sleep or circadian-related impairment across the screening self-reports or interview\n* Living in an English-speaking country (and one that the researchers have expertise in research procedures and diet)\n* Has been speaking English for at least 10 years, speaks English in the home, or certifies that they are able to understand English well for the study and demonstrates this during the screening interview.\n* Receiving medical care for bipolar disorder (referrals will be provided for those who would like to begin care)\n* Mood-stabilizing medication regimens stable for at least one month\n* \\\u003C 5 kg weight change in the past 3 months\n* Currently eating ≥ 12 hours per day at least twice per week\n* Able to operate the camera function and respond to web-based surveys by phone (loaner phones will be provided as needed)\n* Not engaged in current shift work or have other responsibilities such as providing care that would chronically disrupt their sleep (i.e., \\> 3 h between 22:00 and 05:00 h for at least 1 day\u002Fweek)\n* Able to complete 7 days of dietary logs adequately (e.g., at least 2 entries per day, covering at least a 5-hour eating window) during the baseline period\n* Able to complete screening and baseline questionnaires adequately (e.g., not failing more than 1 attention check item with instructed responding; responding to standard multiple-choice items in a mean of \\\u003C 2 seconds per item). Where individuals respond to more than 14 items in a row with the same response, their answers will be manually reviewed for possible invalidity.\n\nExclusion criteria include the following:\n\n* Current episode of depression, hypomania or mania, or psychosis (assessed by the DIAMOND), Participants with acute mood disorder episodes will be encouraged to seek treatment and to consider the study when symptoms have remitted.\n* Eating disorder diagnosis (by self-report of treatment or diagnosis at any point during their life, Short Eating Disorder Examination Questionnaire (EDE-QS) scores above clinical concern thresholds for eating disorders, or DIAMOND interview of symptoms during adulthood)\n* Past 3-month alcohol use disorder or substance use disorder (assessed by DIAMOND)\n* Active suicidal ideation coupled with plan, intent or attempt history as assessed by Columbia Suicide Severity Rating Scale\n* Conditions that would interfere with ability to take part in the intervention, including pregnancy, breastfeeding, uncorrected hypo or hyperthyroidism, gastrointestinal conditions impairing nutrient absorption\n* Conditions that would confound immune or other study measures, such as HIV, AIDS, lupus, or multiple sclerosis\n* Medications contraindicated for fasting: clozapine, glucose-lowering medications, diabetes-related injections, medications requiring food early morning or late evening, corticosteroids; Glucagon-like peptide-1 (GLP-1) agonists will not be an exclusion criteria if weight stabilized\n* Cognitive deficits as noted during the initial interview or as indicated by low performance on the Orientation Memory Concentration Test- Short Version (weighted score \\\u003C 20)","65 Years",{"count":179,"type":20},150,[63],"The goal of this clinical trial is to understand how level of adherence with time-restricted eating (TRE) predicts change in diurnal rhythms (as measured using the amplitude of diurnal peripheral clock gene expression), and how those changes predict lower mania and depressive symptoms, and downstream improvements in quality of life. The effects of diurnal amplitude of clock gene expression is expected to remain significant when controlling for change in glucose tolerance and inflammation. Participants will be enrolled who are already receiving medication treatment for bipolar disorder. Participants will complete daily measures of eating, sleep and mood for two weeks, and then will be assigned to follow TRE for eight weeks. Symptoms and Quality of Life will be measured at baseline and during and after the food plan.",[183,184],"Bipolar Disorder","Time Restricted Eating",[186,187,188],"sleep","insomnia","circadian rhythms","2026-01-12",{"date":191,"type":42},"2026-01-14",{"date":193,"type":42},"2024-11-22",{"date":195,"type":20},"2029-02-01",{"name":48,"class":49},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":58,"sex":16,"minAge":204,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":50},"100515061","niaimproving-function-and-well-being-by-improving-patient-memory-transdiagnostic-sleep-and-circadian-treatment-100515061","NCT05986604","NIA_Improving Function and Well-being by Improving Patient Memory: Transdiagnostic Sleep and Circadian Treatment","NIA_Improving Sleep and Circadian Functioning, Daytime Functioning, and Well-being for Midlife and Older Adults by Improving Patient Memory for a Transdiagnostic Sleep and Circadian Treatment","Inclusion criteria:\n\n1. Aged 50 years and older;\n2. English language fluency;\n3. Experiencing a mobility impairment;\n4. Low income;\n5. Exhibit a sleep or circadian disturbance as determined by endorsing 4 \"quite a bit\" or 5 \"very much\" (or the equivalent for reverse scored items) on one or more PROMIS-SD questions.\n6. 25-30 on the Montreal Cognitive Assessment, as a negative screen for cognitive impairment.\n7. Able\u002Fwilling to give informed consent.\n\nExclusion criteria:\n\n1. Severe untreated sleep disordered breathing (AHI\\>30) or moderate untreated sleep disordered breathing with severe daytime sleepiness (AHI of 15-30 and Epworth Sleepiness Scale \\>10);\n2. Medical conditions that prevent a participant from comprehending and following the basic tenants of treatment (e.g., dementia) or that interfere with sleep in a manner that can't be addressed by a cognitive behavioral treatment (e.g., the Structured Clinical Interview for Sleep Disorders will be used to screen for narcolepsy, REM sleep behavior disorder) or that may preclude full participation (e.g., receipt of end of life care);\n3. Homelessness;\n4. Night shift work \\>2 nights per week in the past 3 months;\n5. Substance abuse\u002Fdependence only if it makes participation in the study unfeasible;\n6. Suicide risk sufficient to preclude treatment on an outpatient basis.","50 Years",{"count":206,"type":20},178,[63],"Mental illness is often chronic, severe, and difficult to treat. Though there has been significant progress towards establishing effective and efficient interventions for psychological health problems, many individuals do not gain lasting benefits from these treatments. The Memory Support Intervention (MSI) was developed utilizing existing findings from the cognitive science literature to improve treatment outcomes. In this study, the investigators aim to conduct an open trial that includes individuals 50 years and older to assess if a novel version of the Memory Support Intervention improves sleep and circadian functioning, reduces functional impairment, and improves patient memory for treatment.",[210,211,212],"Sleep Disorder","Circadian Dysregulation","Memory Impairment","2025-11-18",{"date":215,"type":42},"2025-11-24",{"date":217,"type":42},"2024-01-04",{"date":219,"type":20},"2028-07-28",{"name":48,"class":49},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":58,"sex":16,"minAge":227,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":231,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":50},"100544350","phase-1-investigating-the-persisting-effects-of-a-single-dose-of-psilocybin-on-structural-plasticity-in-healthy-older-adults-100544350","NCT06367738","Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults","Inclusion Criteria:\n\nAre 60-85 years of age at time of Informed Consent Form signing. Are able and willing to adhere to study requirements, including attending all study visits, preparatory and follow-up sessions, and completing all study evaluations.\n\nAre able to swallow capsules. Women of childbearing potential (WOCBP) must agree to practice an effective means of birth control throughout the duration of the study.\n\nHave normal or corrected-to-normal vision as determined by the study staff. Written informed consent obtained from and ability for subject to comply with the requirements of the study.\n\nHave an identified support person and agree to be accompanied home (or to an otherwise safe destination) by the support person, or another responsible party, following dosing.\n\nAgree to inform the investigators within 48 hours of any new or changed medical conditions during the course of their study participation.\n\nHave access to a quiet space and a computer to perform online assessments.\n\nExclusion Criteria:\n\nBreastfeeding, have a positive pregnancy test at screening or at any point during the course of the study, or unwilling to practice birth control during participation in the study.\n\nHave a current psychiatric disorder, general medical condition, or other problem or abnormality that, in the opinion of the study clinician or PI, could compromise safety, render them unsuitable for the study, or would make them unable to comply with study activities.\n\nHave MRI contraindications (e.g., metal implants, pacemakers, claustrophobia etc.) as determined by an MRI contraindications questionnaire.\n\nHave a history of recent, clinically significant suicidal ideation or behavior.\n\nHave a history of a psychotic disorder, bipolar disorder (type I or II), or a dissociative disorder (determined by history).\n\nHistory of Hallucinogen Persisting Perception Disorder (HPPD). History of a seizure disorder in adulthood, central nervous system (CNS) metastases or current symptomatic CNS infection.\n\nHistory of intracerebral hemorrhage, embolic stroke, transient ischemic attack (TIA), or history of any aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial and peripheral arterial vessels) or arteriovenous malformation.\n\nHistory of valvulopathy or pulmonary hypertension. Uncontrolled hypertension (Systolic BP\\>139mmHG or Diastolic BP\\>89mmHG) or tachycardia (average HR\\>90bpm) averaged over at least two measurements.\n\nClinically significant cardiovascular disease (e.g., history of myocardial infarction or congestive heart failure); or baseline QT\u002FQTc\\>500msec; or baseline QT\u002FQTc 451-500msec with repeat QT\u002FQTc \\>500msec.\n\nPoorly controlled diabetes mellitus (e.g., history of an episode of severe hypoglycemia or hospitalization for hyperglycemia on the current diabetes regimen).\n\nInadequate hepatic function as determined by total bilirubin or alkaline phosphatase \\>3x institutional upper limit of normal; or AST or ALT \\>6x institutional upper limit of normal. However, participants with Gilbert syndrome are allowed to enroll.\n\nInadequate renal function as determined by eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 (based on the MDRD equation) or CrCl \\\u003C 30 mL\u002Fmin (based on the C-G equation).\n\nThe regular use of psychotropic medications, such as antidepressants (i.e., SSRIs, tricyclic antidepressants, and monoamine oxidase inhibitors), antipsychotics, and mood stabilizers.\n\nConcomitant dosing of psilocybin with known UGT1A10 and UGT1A9 inhibitors (e.g., diclofenac and probenecid) will be avoided. \\[There is no exclusion criterion based on the use of medications or substances that are inhibitors or inducers of CYP450 enzymes.\\]\n\nThe use of Prohibited Medications:\n\nSerotonin Reuptake Inhibitors (SSRIs and SNRIs) Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Atypical antidepressants (e.g., mirtazapine, trazodone, buspar) Antipsychotics\u002FNeuroleptics (typical and atypical) Anti-epileptics or mood stabilizers (e.g., lithium, valproate) (does not include gabapentin used for non-epilepsy conditions) Efavirenz (Sustiva, in Atripla) Lorcaserin Over-the-counter supplements intended to affect mood or anxiety (e.g., 5HT-P, SAMe or St. John's Wort).\n\nOther drugs associated with the serotonin syndrome (e.g., ondansetron) used within 48 hours of study drug administration.\n\nVasoactive drugs (e.g., sildenafil, sumatriptan, calcium channel blockers) used within 48 hours of study drug administration.\n\nUnable to agree to the following required Lifestyle Modifications: Patients will be asked to refrain from consuming alcohol, cannabinoids, prescription analgesics\u002Fstimulants\u002Fbenzodiazepines, and any recreational drugs for 48 hours before, the day of, and for 48 hours after study drug administration. Participants will be advised to consume their usual amount of coffee, tea, or other caffeine-containing beverages on the morning of their Medication Visits.\n\nRecent and lifetime use of psychedelics (e.g. psilocybin, LSD, mescaline), entactogens (e.g. MDMA), or dissociative anesthetics (e.g. ketamine) above a predetermined threshold.\n\nHas been diagnosed with any disease that impairs motor function (e.g., Parkinson's disease) At high risk of falls as determined by study physician considering medical history, screening of recent symptoms and medications, and functional mobility testing.","60 Years","85 Years",{"count":230,"type":20},40,[232],"PHASE1","Participants in this study will undergo a series of non-invasive tests and activities designed to understand how a single dose of psilocybin might influence cognition and emotional well-being in healthy older adults. After providing written informed consent, eligible participants, aged between 60 and 85, will be randomly assigned to receive a dose of psilocybin ranging from a microdose to a moderate-to-high dose. Anatomical magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) will be used to assess changes in brain structure, while functional magnetic resonance imaging (fMRI) will be used to quantify changes in functional brain activity.",[235],"Aging","2025-10-17",{"date":238,"type":42},"2025-10-21",{"date":240,"type":20},"2025-11",{"date":242,"type":20},"2027-12-30",{"name":48,"class":49},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":58,"sex":16,"minAge":250,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":50},"100459663","phase-1-investigating-the-mechanisms-of-the-effects-of-psilocybin-on-visual-perception-and-visual-representations-in-the-brain-100459663","NCT05265546","Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain","Inclusion Criteria:\n\n1. Are ≥21 years of age at time of Informed Consent Form signing\n2. Are able and willing to adhere to study requirements, including attending all study visits, preparatory and follow-up sessions, and completing all study evaluations.\n3. Are able to swallow capsules.\n4. Women of childbearing potential (WOCBP) must agree to practice an effective means of birth control throughout the duration of the study.\n5. Written informed consent obtained from and ability for subject to comply with the requirements of the study.\n6. Have an identified support person and agree to be accompanied home (or to an otherwise safe destination) by the support person, or another responsible party, following dosing.\n7. Agree to inform the investigators within 48 hours of any new or changed medical conditions during the course of their study participation.\n\nExclusion Criteria:\n\n1. Breastfeeding, have a positive pregnancy test at screening or at any point during the course of the study, or unwilling to practice birth control during participation in the study.\n2. Have a current psychiatric disorder, general medical condition, or other problem or abnormality that, in the opinion of the study clinician or PI, could compromise safety, render them unsuitable for the study, or would make them unable to comply with study activities.\n3. Have MRI contraindications (e.g., metal implants, pacemakers, claustrophobia etc.) as determined by an MRI contraindications questionnaire.\n4. Uncontrolled hypertension (Systolic BP\\>139mmHG or Diastolic BP\\>89mmHG) or tachycardia (average HR\\>90bpm) averaged over at least two measurements.\n5. Clinically significant cardiovascular disease (e.g., history of myocardial infarction or congestive heart failure); or baseline QT\u002FQTc\\>500msec; or baseline QT\u002FQTc 451-500msec with repeat QT\u002FQTc \\>500msec.\n6. Inadequate hepatic function as determined by total bilirubin or alkaline phosphatase \\>3x institutional upper limit of normal; or AST or ALT \\>6x institutional upper limit of normal. However, participants with Gilbert syndrome are allowed to enroll.\n7. Inadequate renal function as determined by eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 (based on the MDRD equation) or CrCl \\\u003C 30 mL\u002Fmin (based on the C-G equation).\n8. The regular use of psychotropic medications, such as antidepressants (i.e., SSRIs, tricyclic antidepressants, and monoamine oxidase inhibitors), antipsychotics, and mood stabilizers.\n9. Concomitant dosing of psilocybin with known UGT1A10 and UGT1A9 inhibitors (e.g., diclofenac and probenecid) will be avoided. \\[There is no exclusion criterion based on the use of medications or substances that are inhibitors or inducers of CYP450 enzymes.\\]\n10. The use of Prohibited Medications:\n\n    Serotonin Reuptake Inhibitors (SSRIs and SNRIs) Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Atypical antidepressants (e.g., mirtazapine, trazodone, buspar) Antipsychotics\u002FNeuroleptics (typical and atypical) Anti-epileptics or mood stabilizers (e.g., lithium, valproate) (does not include gabapentin used for non-epilepsy conditions) Efavirenz (Sustiva, in Atripla) Lorcaserin Over-the-counter supplements intended to affect mood or anxiety (e.g., 5HT-P, SAMe or St. John's Wort).\n\n    Other drugs associated with the serotonin syndrome (e.g., ondansetron) used within 48 hours of study drug administration (70).\n\n    Vasoactive drugs (e.g., sildenafil, sumatriptan, calcium channel blockers) used within 48 hours of study drug administration.\n11. Unable to agree to the following required Lifestyle Modifications: Patients will be asked to refrain from consuming alcohol, cannabinoids, prescription analgesics\u002Fstimulants\u002Fbenzodiazepines, and any recreational drugs for 48 hours before, the day of, and for 48 hours after study drug administration. Participants will be advised to consume their usual amount of coffee, tea, or other caffeine-containing beverages on the morning of their Medication Visits.\n12. Have a recent history of suicidal ideation or attempted suicide that, in the opinion of the study clinician or PI, may present a risk of suicidal or self-injurious behavior.\n13. Have received an investigational drug or taken a psychedelic within 30 days of the screening visit.\n14. Have an allergy or intolerance to any of the materials contained in the investigational drug product.","21 Years",{"count":252,"type":20},80,[232],"The long-term objective of this project is to characterize how psilocybin affects visual perception and the brain's representation of the visual environment. It is known that psilocybin alters aspects of visual perception, but the underlying brain mechanisms contributing to these effects are poorly understood. The proposed work will address these questions in a large, diverse sample of healthy human subjects by using functional magnetic resonance imaging (fMRI) to measure the brain's responses to visual stimuli. The proposed research will document which brain areas mediate the effects of psilocybin. The technique of fMRI will be employed to measure brain activity in different brain areas while subjects are performing a visual perceptual task.",[256],"Perception Disorders",{"date":238,"type":42},{"date":259,"type":42},"2024-03-08",{"date":261,"type":20},"2025-12-31",{"name":48,"class":49},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":21,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":50},"100607304","support-from-peers-to-expand-access-study---community-100607304","NCT07186816","SUpport From PEeRs to Expand Access Study - Community","SUPERA: Supporting Peer Interactions to Expand Access to Digital Cognitive Behavioral Therapy for Spanish-speaking in the San Francisco Mission Community","SUPERA","Inclusion Criteria:\n\n1. PHQ-9 ≥ 10 or GAD-7 ≥ 8\n2. Has access to the Internet via smartphone and\u002For broadband at home, and basic level of technological literacy or willingness to undergo a brief technology use training\n3. ≥18 years of age\n4. Preference for receiving medical care in Spanish\n5. Not in concurrent psychotherapy\n6. If currently taking an antidepressant medication, patient must have been on a stable dose for at least 6 weeks, and have no plans to change the dose. We will permit patients on antidepressants to enter the study, as this will increase generalizability. Antidepressant status will be monitored at each assessment to control for those effects, if necessary.\n\nExclusion Criteria:\n\n1. Currently receiving psychotherapy, as this treatment will be offered as a frontline treatment for depression and anxiety, however, patients are allowed to be referred to treatment while participating in this study and initiation of treatment will be monitored and considered in analyses\n2. Visual, hearing, voice, or motor impairment or illiteracy that would prevent completion of study procedures\n3. Diagnosis of a psychotic disorder, bipolar disorder, dissociative disorder, or substance use disorder\n4. Severe suicidality (as assessed by expressing suicidal ideation, plan, and intent). Although procedures with back-up plans are in place for patients who develop suicidality (see Human Subjects Section), patients assessed with severe suicidality will be referred to more-intensive treatment resources.","100 Years",{"count":273,"type":20},213,[63],"Investigators will evaluate the implementation of an evidence-based, Spanish-language, digital, cognitive-behavioral therapy (dCBT) intervention (SilverCloud) in the Mission community for Latino patients with depression and\u002For anxiety. 213 participants will be enrolled in a one-armed trial comparing self-guided vs. supported dCBT (SilverCloud).",[277],"Depression, Anxiety","2025-09-18",{"date":280,"type":42},"2025-09-22",{"date":282,"type":42},"2025-08-18",{"date":284,"type":20},"2027-03-01",{"name":48,"class":49},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":58,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":21,"phases":296,"briefSummary":297,"conditions":298,"keywords":304,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":79},"100579442","clean-trial---chlorination-to-reduce-enteric-and-antibiotic-resistant-infections-in-neonates-100579442","NCT06824350","Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates","Multi-component Chlorination Intervention to Reduce Neonatal Infections in Rural Health Facilities","CLEAN","Facility Inclusion Criteria:\n\n* Public health care facility\n* 25 live births or more per month\n* Infrastructure compatible with inline chlorination device\n\nParticipant Inclusion Criteria:\n\n* Pregnant adults\u002Fmature minors arriving at enrolled facilities to give birth and their neonates\n\nFacility Exclusion Criteria:\n\n* Existing facility-level chlorination\n\nParticipant Exclusion Criteria:\n\n* Miscarriage (\\\u003C28 weeks gestation)\n* Stillbirth (for neonatal analysis only)\n* Unable to give informed consent\u002Fdo not consent\n* Reside \\>2 hours away from facility for enrollment into swab sampling cohort",{"count":295,"type":20},45450,[63],"The CLEAN (ChLorine to reduce Enteric and Antibiotic resistant infections in Neonates) cluster randomized controlled trial in western Kenya will evaluate the impact of a multi-component chlorination intervention in health care facilities on maternal and neonatal health. Intervention facilities will receive a passive chlorination technology for water supply treatment and a reliable supply of sodium hypochlorite disinfectant. Both intervention and treatment facilities will receive infection prevention and control messaging. The goal of the study is to evaluate the impact of the intervention on bacterial contamination of water supply, on staff hands, and on high-touch surfaces in maternity wards, and the following outcomes among facility-born neonates and their mothers: (1) gut carriage of bacterial pathogens associated with sepsis one week post-birth, (2) gut carriage of antibiotic resistant bacteria one week post-birth, and (3) symptoms of possible serious bacterial infection one week following birth.",[299,300,301,302,303],"Sepsis","Neonatal Mortality","Antibiotic Resistant Infection","Enteric Infections","Serious Bacterial Infection",[305,306,307,308,309,310,311,312,313],"infection prevention and control","antibiotic resistance","bacterial enteric infection","neonatal mortality","sepsis","water disinfection","chlorine","sodium hypochlorite","hospital acquired infections","2025-05-20",{"date":316,"type":42},"2025-05-25",{"date":318,"type":42},"2025-01-21",{"date":320,"type":20},"2027-07",{"name":48,"class":49},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":329,"minAge":330,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":21,"phases":333,"briefSummary":334,"conditions":335,"keywords":339,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":348,"locationsCount":4},"100589593","mitigating-heat-stress-among-rickshaw-drivers-in-bangladesh-100589593","NCT06956430","Mitigating Heat Stress Among Rickshaw Drivers in Bangladesh","How Does Heat Stress Affect Telomere Length? A Pilot Randomized Controlled Trial in Urban Bangladesh","Inclusion Criteria:\n\n* Reports driving a manual rickshaw at least five days per week for at least 8 hours per day for the past 12 months\n\nExclusion Criteria:\n\n* Reports driving a battery-powered rickshaw in the past 12 months\n* Has hypertension, as measured by our study staff\n* Has diabetes, as measured by our staff\n* Reports diagnosis with cardiovascular disease \u002F chronic cardiac condition\n* Reports diagnosis with respiratory disease \u002F chronic respiratory condition","MALE","40 Years",{"count":332,"type":20},300,[63],"The goal of the experimental study is to understand the impact of heat stress on core temperature and telomere length. Investigators will recruit rickshaw drivers who use manual power to push their rickshaws and randomly assign half of them to receive battery-powered rickshaws to use for four months. Investigators will assess how this change impacts their core body temperature while they work, the length of their telomeres (caps on the end of DNA that are associated with aging), and kidney function.",[336,337,338],"Core Temperature","Telomere Length, Mean Leukocyte","Kidney Function Issue",[132,340,341,134,135,136,137],"heat strain","rickshaw","2025-05-15",{"date":344,"type":42},"2025-05-21",{"date":346,"type":20},"2025-06-01",{"date":261,"type":20},{"name":48,"class":49},{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":21,"phases":358,"briefSummary":359,"conditions":360,"keywords":362,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":50},"100588882","vaccine-confidence-and-infodemic-in-southeast-asias-nusantara-sociocultural-sphere-100588882","NCT06947187","Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere","Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere: A Transdisciplinary, Transnational Study","Inclusion Criteria:\n\n* At least 18 years old\n* Live in Brunei, Indonesia, Malaysia, or Singapore\n* Fluent in Bahasa Melayu or Bahasa Indonesia\n* Watch social media content in Bahasa Melayu or Bahasa Indonesia every day\n* Access to stable Internet on smartphone or laptop to complete the experiment without interruption\n\nExclusion Criteria:\n\n* Individuals who were involved in the online human-centered design thinking workshops or the in-person focus-group discussions will not be eligible to participate in RCT. This exclusion criterion is put in place to prevent potential bias in the evaluation of the intervention's effectiveness.\n* Individuals who have difficulty in looking at social media on cellphone (even when they use prescription glasses), listening to the audio of social media content on cellphone (even with hearing aid), and typing within or engaging with social media content on cell phone are not eligible to participate in this study. -",{"count":357,"type":20},472,[63],"The goal of this clinical trial is to understand how well a culturally-specific \"prebunking\" video can improve vaccine information literacy and vaccine confidence among individuals in the Nusantara sociocultural sphere. The investigators hypothesize the individuals who watch the co-created \"prebunking\" intervention video will have improved vaccine literacy skills and vaccine confidence compared to individuals who watch a video about safe medication disposal.",[361],"Misinformation",[361,363,364,365,366],"Bahasa","Vaccine confidence","Vaccine literacy","Video intervention","2025-04-19",{"date":369,"type":42},"2025-04-27",{"date":371,"type":42},"2024-12-28",{"date":373,"type":20},"2026-06-01",{"name":48,"class":49},{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":177,"enrollmentInfo":383,"targetDuration":4,"studyType":21,"phases":384,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":50},"100530590","healthy-lifestyles-for-bipolar-disorder-100530590","NCT06188754","Healthy Lifestyles for Bipolar Disorder","Time-restricted Eating vs. Mediterranean Diet as Adjunctive Interventions for Bipolar Disorder","HL","Inclusion Criteria:\n\n* meets diagnostic criteria for bipolar I disorder or bipolar II disorder (but not cyclothymia, BD Not otherwise specified or BD due to another medical condition)\n* current sleep (insomnia, hypersomnolence) or circadian sleep-wake (delayed phase, advanced phase, irregular sleep-wake, non-24-hour sleep-wake-type) concerns indicated by endorsement of at least some sleep or circadian-related impairment across the screening self-reports or interview\n\n  * Living in an English-speaking country (and one that we have expertise in research procedures and diet)\n  * Has been speaking English for at least 10 years, speaks English in the home, or certifies that they are able to understand English well for the study and demonstrates this during the screening interview.\n  * Receiving medical care for BD (referrals will be provided for those who would like to begin care)\n  * Mood-stabilizing medication regimens stable for at least one month\n  * \\\u003C 5 kg weight change in the past 3 months\n  * Currently eating ≥ 12 hours per day at least twice per week\n  * Able to operate the camera function and respond to web-based surveys by phone (loaner phones will be provided as needed)\n  * Not engaged in current shift work or have other responsibilities such as providing care that would chronically disrupt their sleep (i.e., \\> 3 h between 22:00 and 05:00 h for at least 1 day\u002Fweek)\n  * Able to complete 7 days of dietary logs adequately (e.g., at least 2 entries per day, covering at least a 5-hour eating window) during the baseline period\n  * Able to complete screening and baseline questionnaires adequately (e.g., not failing more than 1 attention check item with instructed responding; responding to standard multiple-choice items in a mean of \\\u003C 2 seconds per item). Where individuals respond to more than 14 items in a row with the same response, we will manually review for possible invalidity.\n\nExclusion criteria include the following:\n\n* Current episode of depression, hypomania or mania, or psychosis (assessed by the aDiagnostic Interview for Anxiety, Mood, and Obsessive-compulsive and Related Neuropsychiatric Disorders; DIAMOND), Participants with acute mood disorder episodes will be encouraged to seek treatment and to consider the study when symptoms have remitted.\n* Eating disorder diagnosis (by self-report of treatment or diagnosis at any point during their life, Short Eating Disorder Examination Questionnaire (EDE-QS) scores above clinical concern thresholds for eating disorders, or DIAMOND interview of symptoms during adulthood)\n* Past 3-month alcohol use disorder or substance use disorder (assessed by DIAMOND)\n* Active suicidal ideation coupled with plan, intent or attempt history as assessed by Columbia Suicide Severity Rating Scale\n* Conditions that would interfere with ability to take part in the intervention , including pregnancy, breastfeeding, uncorrected hypo or hyperthyroidism, gastrointestinal conditions impairing nutrient absorption,\n* Medical conditions such as HIV, AIDS, lupus, or multiple sclerosis that could confound the assessment of mania or other measures\n* Medications contraindicated for fasting: clozapine, glucose-lowering medications, diabetes-related injections, medications requiring food early morning or late evening, corticosteroids; medications such as semaglutide will not be an exclusion criteria\n* Cognitive deficits as noted during the initial interview or as indicated by low performance on the Short Orientation Memory Concentration Test (\\\u003C 20 on the weighted score).",{"count":332,"type":20},[63],"The goal of this clinical trial is to compare the effects of two different healthy lifestyles on outcomes for those with bipolar disorder. The goals are to understand the acceptability of time-restricted eating and the mediterranean diet for those who are already receiving medication treatment for bipolar disorder, and to consider how these two food plans predict changes in manic symptoms, depressive symptoms, and Quality of Life. Participants will complete daily measures of eating, sleep and mood for two weeks, and then will be assigned to follow one of the two food plans for eight weeks. The investigators will measure symptoms and Quality of Life at baseline and during and after the food plan.",[184,387],"Diet, Mediterranean",[389,186,390],"bipolar disorder","circadian rhythm","2025-02-03",{"date":393,"type":42},"2025-02-06",{"date":395,"type":42},"2024-06-05",{"date":397,"type":20},"2029-02-28",{"name":48,"class":49},""]